53981-25-2

Usage

Chemical Properties

Purple crystals

Uses

A metabolite of halogenated aniline.

InChI:InChI=1/C6H6FNO/c7-4-2-1-3-5(8)6(4)9/h1-3,9H,8H2

Upstream product

• 1526-17-6 2-fluoro-6-nitrophenol 

Downstream Products

• 112808-48-7 2-(2-bromo-3-methylbutyryl)amino-6-fluorophenol 
• 153403-54-4 2-mercapto-7-fluorobenzoxazole 
• 560082-51-1 8-fluoro-3,4-dihydro-2H-1,4-benzoxazin-3-one 
• 1350659-93-6 9-fluoro-5-[5-(3-morpholin-4-ylphenoxy)pyrimidin-2-yl]-2,3,4,5-tetra-hydro-benzo[b][1,4]oxazepine 
• 35048-10-3 7-fluoro-8-hydroxyquinoline 

Relevant academic research and scientific papers

COMPOUND HAVING ZNF143 INHIBITORY ACTIVITY AND USE THEREOF

PROBLEM TO BE SOLVED: To provide a compound having a ZNF143 inhibitory activity as well as to provide a ZNF143 inhibitory agent and pharmaceutical composition containing the same. SOLUTION: Provided is a compound represented by formula (I) or a salt thereof as well as a ZNF143 inhibitory agent containing the same and a pharmaceutical composition having the same as an active ingredient. A-B-C-D (I)[A is H, a methyl group, a naphthyl group, a phenyl group or a nitrogen-containing heterocyclic ring; B is as shown below, and C is an amide bond or a heteroaromatic ring containing N and O; D is a substituted/unsubstituted phenyl group or a monocyclic heteroaromatic ring containing N or S; and C and D are both fused heterocyclic ring or the like optionally having a substituent group.]. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2016,JPOandINPIT

2-Aminobenzoxazole ligands of the hepatitis C virus internal ribosome entry site

2-Aminobenzoxazoles have been synthesized as ligands for the hepatitis C virus (HCV) internal ribosome entry site (IRES) RNA. The compounds were designed to explore the less basic benzoxazole system as a replacement for the core scaffold in previously discovered benzimidazole viral translation inhibitors. Structure-activity relationships in the target binding of substituted benzoxazole ligands were investigated.

N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS

The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to novel compounds of formula (I) wherein W, n, X and W’ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors - subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.

BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES

The present invention relates to benzoxazolone derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, in the treatment of movement disorders, in particular in Parkinson's disease.

Oxamide inhibitors of plasminogen activator inhibitor-1

Methods of treating disorders associated with elevated levels of PAI-1 are disclosed comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of formula at least one compound of formula (I), or a pharmaceutically-acceptable salt, prodrug, stereoismer or solvate thereof, wherein: A is aryl or heteroaryl, X is O or S, and R1-R9 and R18 are defined herein. The invention also pertains to pharmaceutical compositions and compounds within the scope of formula (I) as well as medicaments and articles of manufacture comprising compounds of formula (I).